CNS Therapeutics Markets, 2016-2024 - Global Strategic Business Report 2017

Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants & Others - Seite 2

Patent Expiries of Major Anti-Epilepsy Drugs
High Unmet Needs Offer Scope for Market Growth
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
Refractory Childhood Epilepsy & Pregnancy Epilepsy
Major Concerns
Review of Anti-Epilepsy Drugs
Vimpat
Keppra
Lamictal
Tegretol
Sabril
Perampanel
Zonegran
Topamax
Trileptal
Neurontin
Lyrica
Depakine
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Select Phase III Completed Studies for Cancer Pain
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Minimally Invasive Procedures Gain Popularity for Chronic Back Pain
Neuropathic Pain Management: Market with High Potential
Select Phase III Completed Studies for Neuropathic Pain
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
New Pain Management Drugs
Recent Approvals in Pain Management: 2016-2017
Select Pain Management Drugs
Flupirtine
Lyrica
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
Anti-Alzheimer's
Market Overview
Treatment for Alzheimer's
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer's Drugs
Drug Development Scenario for Alzheimer's
Major Focus on Amyloid Targets
Aducanumab
A Promising Drug for Alzheimer's Disease
Phase III Pipeline Drugs for Alzheimer's Disease
Prevention Gains Increasing Attention
Novel Treatment for Alzheimer's to Emerge
Evolving Brain Imaging Technologies to Offer Early and Greater Accuracy
A Review of Select Anti-Alzheimer's Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
Anti-Inflammatory Drug, Ponstel, Displays Potential to Treat Alzheimers in Mice
Anti-Parkinson's
Market Overview
Levodopa
The Gold Standard for Parkinson's Treatment
Xadago
New Approved Add-On Therapy for Parkinson's Disease
NUPLAZID
The First and the Only Approved Drug for Psychosis related to Parkinson's disease
MSDC-0160
A Potential Drug Undergoing Animal Studies
Select Anti-Parkinson's Drugs
Levodopa
Dopamine Agonists
Mirapex
Requip
Anti-Depressants